SLS

SELLAS Life Sciences Group, Inc. NASDAQ Listed Mar 12, 2008

Healthcare ·Biotechnology ·US · sellaslifesciences.com

$4.93

Mkt Cap $702.2M

52w Low $1.36 74.7% of range 52w High $6.14

50d MA $4.95 200d MA $3.02

P/E (TTM) -19.7x

EV/EBITDA -12.0x

P/B 7.6x

Debt/Equity 0.0x

ROE -37.9%

P/FCF -14.5x

RSI (14) —

ATR (14) —

Beta 2.23

50d MA $4.95

200d MA $3.02

Avg Volume 6.4M

SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.

SIC Code

2834

CIK (SEC)

1390478

Phone

646 200 5278

Times Square Tower · New York City, NY 10036 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 19, 2026	AMC	-0.06	-0.05	+21.0%	5.20	+7.7%	-8.5%	+5.4%	-3.8%	+1.9%	-4.8%	—
Nov 12, 2025	AMC	-0.06	-0.06	+5.2%	1.49	+0.7%	-2.0%	-4.0%	-5.4%	+6.7%	+2.0%	—
Aug 12, 2025	AMC	-0.08	-0.07	+16.0%	1.61	+0.6%	-3.7%	-3.7%	+1.2%	+7.5%	+5.6%	—
May 13, 2025	AMC	-0.10	-0.07	+30.0%	1.41	+4.3%	+7.1%	+13.5%	+15.6%	+24.1%	+37.6%	—
Mar 20, 2025	AMC	-0.11	-0.08	+27.3%	1.21	-6.6%	-0.8%	+1.7%	+0.8%	-2.5%	-4.1%	—
Nov 13, 2024	AMC	-0.13	-0.10	+23.1%	1.27	+0.8%	+0.0%	+3.9%	+1.6%	+1.6%	-2.4%	—
Aug 13, 2024	AMC	-0.16	-0.13	+18.8%	1.19	+0.0%	+0.8%	+6.7%	+10.9%	+16.8%	+10.1%	—
May 14, 2024	AMC	-0.16	-0.21	-31.2%	1.37	-1.5%	+7.3%	+7.3%	+6.6%	+8.0%	+3.6%	—
Mar 28, 2024	AMC	0.09	-0.25	-388.5%	1.01	+2.0%	+5.9%	+16.8%	+29.7%	+27.7%	+32.7%	—
Nov 9, 2023	AMC	-0.03	-0.33	-1200.2%	0.91	-2.2%	-0.2%	-3.3%	-0.3%	+6.6%	+1.2%	—
Aug 10, 2023	AMC	-0.35	-0.31	+11.4%	1.57	-0.6%	-1.3%	-3.2%	-5.1%	-9.6%	-9.6%	—
May 11, 2023	AMC	-0.29	-0.47	-62.1%	1.71	-0.6%	-11.1%	-4.1%	-7.6%	-1.2%	-0.6%	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Mar 12	Maxim Group	Maintains	Buy → Buy	—	$5.48	$5.52	+0.7%	-8.2%	-2.0%	-2.2%	-8.0%	-9.7%
Jul 16	Maxim Group	Maintains	Buy → Buy	—	$1.90	$1.91	+0.5%	+1.1%	+0.0%	-6.8%	-2.6%	-3.2%
Nov 22	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$0.97	$0.99	+2.0%	+4.1%	+8.2%	+3.1%	+9.3%	+8.2%
Sep 7	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$1.44	$1.42	-1.4%	+2.1%	+10.4%	+4.9%	+4.9%	+5.6%
Nov 15	Alliance Global Partners	Maintains	Buy → Buy	—	$2.55	$2.50	-2.0%	-12.2%	-3.9%	+3.1%	+2.0%	+1.2%
Jun 28	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$2.32	$2.39	+3.0%	-4.7%	-2.6%	-3.9%	-5.2%	+2.2%
Jul 21	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$8.60	$9.00	+4.7%	+8.1%	+4.5%	+2.1%	+0.8%	-1.2%
Nov 18	Alliance Global Partners	Maintains	Buy → Buy	—	$5.15	$4.23	-17.9%	-18.4%	-14.8%	-16.5%	-22.3%	-23.9%
Nov 18	Oppenheimer	Maintains	Outperform → Outperform	—	$5.15	$4.23	-17.9%	-18.4%	-14.8%	-16.5%	-22.3%	-23.9%
Nov 18	Maxim Group	Upgrade	Hold → Buy	—	$5.15	$4.23	-17.9%	-18.4%	-14.8%	-16.5%	-22.3%	-23.9%
Nov 18	Maxim Group	Maintains	Buy → Buy	—	$5.15	$4.23	-17.9%	-18.4%	-14.8%	-16.5%	-22.3%	-23.9%
Nov 15	Maxim Group	Upgrade	Hold → Buy	—	$6.17	$6.25	+1.3%	-16.5%	-31.9%	-28.8%	-30.3%	-35.2%
Apr 8	Alliance Global Partners	Maintains	Buy → Buy	—	$51.50	$53.50	+3.9%	+5.8%	+14.6%	+7.8%	+3.9%	+1.0%
Nov 1	Oppenheimer	Maintains	Outperform → Outperform	—	$61.00	$73.50	+20.5%	+36.1%	+46.7%	+51.6%	+45.1%	+42.6%
Jul 20	Maxim Group	Maintains	Buy → Buy	—	$76.50	$92.50	+20.9%	+1.3%	-7.8%	-13.7%	-15.0%	-19.6%
Apr 2	H.C. Wainwright	Maintains	Buy → Buy	—	$172.50	$280.00	+62.3%	+150.7%	+160.0%	+94.2%	+100.0%	+98.6%
Mar 19	Maxim Group	Upgrade	Hold → Buy	—	$239.50	$267.00	+11.5%	-0.8%	-19.2%	-14.2%	-12.3%	-16.1%

Data updated apr 27, 2026 1:47am · Source: massive.com